Laverdeur, E., Peulen, O., Bellahcene, A., Genbauffe, A., Rademaker, G., & Peiffer, R. (11 June 2026). Identification of the role of myoferlin in pancreatic cancer desmoplasia [Poster presentation]. GIGA day. |
Laverdeur, E., Peulen, O., Bellahcene, A., Rademaker, G., Peiffer, R., & Genbauffe, A. (22 May 2026). Identification of the role of myoferlin in immune regulation in pancreatic cancer [Poster presentation]. EDT. |
Shostak, K., Chen, Y., Maurizy, C., Rademaker, G., Xu, X., Blomme, A., Close, P., Renson, O., Van Hul, M., Cani, P. D., Klein, S., Florin, A., Büttner, R., Cataldo, D., Delvenne, P., Nemazanyy, I., WATHIEU, C., Hego, A., Ormenese, S., ... Chariot, A. (2026). The lipid transfer protein STARD7 controls intestinal tumor development in a context-dependent manner. EMBO Molecular Medicine. doi:10.1038/s44321-026-00409-5 |
Gullo, C.* , Laverdeur, E.* , Dancre, M., Peiffer, R., Boumahd, Y., Agirman, F., Maloujahmoum, N., Désiront, L., Thiry, M., Rademaker, G., Bellahcene, A., & Peulen, O. (28 November 2025). Focal adhesion assembly and cell migration require myoferlin in PDAC cell lines. Scientific Reports, 15 (1). doi:10.1038/s41598-025-27134-2 * These authors have contributed equally to this work. |
Peiffer, R., Laverdeur, E., Gaigneaux, A., Boumahd, Y., Gullo, C., Rademaker, G., Crake, R., Lavergne, A., Maloujahmoum, N., Agirman, F., Herfs, M., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (2025). Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. EMBO Journal. doi:10.1038/s44318-025-00570-6 |
Rademaker, G., Hernandez, G. A., Seo, Y., Dahal, S., Miller-Phillips, L., Li, A. L., Peng, X. L., Luan, C., Qiu, L., Liégeois, M., Wang, B., Wen, K. W., Kim, G. E., Collisson, E. A., Kruger, S. F., Boeck, S., Ormanns, S., Guenther, M., Heinemann, V., ... Perera, R. M. (2025). PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Nature. doi:10.1038/s41586-025-09017-8 |
Jain, A., Heremans, I., Rademaker, G., Detomasi, T. C., Rohweder, P., Anderson, D., Zhang, J., Hernandez, G. A., Gupta, S., von Linde, T., Lange, M., Spacci, M., Luo, J., Citron, Y. R., Olzmann, J. A., Dawson, D. W., Craik, C. S., Bommer, G., Perera, R. M., & Zoncu, R. (28 March 2025). Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. Science, 387 (6741), 8331. doi:10.1126/science.adq8331 |
Kovalski, J. R., Sarioglu, G., Subramanyam, V., Hernandez, G., Rademaker, G., Oses-Prieto, J. A., Slota, M., Mohan, N., Yiakis, K., Liu, I., Wen, K. W., Kim, G. E., Miglani, S., Burlingame, A. L., Goodarzi, H., Perera, R. M., & Ruggero, D. (2025). Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity. Nature Cell Biology. doi:10.1038/s41556-024-01604-7 |
Rademaker, G. (22 January 2025). PCSK9 dependent cholesterol acquisition and utilization underlies metastatic organ preference in pancreatic cancer [Paper presentation]. University California Pancreatic cancer conference, San Francisco, United States - California. |
Rademaker, G. (13 February 2024). Differential acquisition of extracellular lipid dictates metastatic organ preference in pancreatic cancer [Paper presentation]. Keystone Metabolism in cancer, Banff, Canada. |
Rademaker, G. (26 September 2023). Differential acquisition of extracellular lipid correlates with pancreatic cancer subtype and metastatic tropism [Poster presentation]. AACR Pancreatic cancer, Boston, United States - Massachusetts. |
Lemaitre, F., Chakrama, F., O'Grady, T., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F., & Habraken, Y. (30 May 2023). The transcription factor c-Jun mediates specific reprogramming of pre-mRNA splicing during platinum-based therapy via RBM39 [Poster presentation]. 28th Annual International Conference of the RNA society RNA 2023, Singapore. |
Rademaker, G. (16 May 2023). Differential acquisition of extracellular lipid correlates with divergent metabolic vulnerabilities in pancreatic cancer [Poster presentation]. Mechanisms of Metabolic Signaling, Cold Spring Harbor, United States - New York. |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V., & Peulen, O. (02 March 2023). Correction: Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis, 12 (1), 11. doi:10.1038/s41389-023-00455-5 |
Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (09 December 2022). The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress. Nucleic Acids Research, 50 (22), 12768 - 12789. doi:10.1093/nar/gkac1130 * These authors have contributed equally to this work. |
Ravichandran, M., Hu, J., Cai, C., Ward, N. P., Venida, A., Foakes, C., Kuljanin, M., Yang, A., Hennessey, C. J., Yang, Y., Desousa, B. R., Rademaker, G., Staes, A. A. L., Cakir, Z., Jain, I. H., Aguirre, A. J., Mancias, J. D., Shen, Y., DeNicola, G. M., & Perera, R. M. (02 September 2022). Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer. Cancer Discovery, 12 (9), 2198 - 2219. doi:10.1158/2159-8290.CD-22-0044 |
Rademaker, G.* , Boumahd, Y.* , Peiffer, R., Anania, S., Wissocq, T., Liégeois, M., Luis, G., Sounni, N. E., Agirman, F., Maloujahmoum, N., De Tullio, P., Thiry, M., Bellahcene, A., Castronovo, V., & Peulen, O. (July 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biology, 53, 102324. doi:10.1016/j.redox.2022.102324 * These authors have contributed equally to this work. |
Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (22 June 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells [Poster presentation]. EACR 2022. |
Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation on the involvement of STAT3 [Paper presentation]. GIGA Day 2022, Liège, Belgium. |
Rademaker, G., Costanza, B., Pyr Dit Ruys, S., Peiffer, R., Agirman, F., Maloujahmoum, N., Vertommen, D., Turtoi, A., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2022). Paladin, overexpressed in colon cancer, is required for actin polymerisation and liver metastasis dissemination. Oncogenesis, 11, 42. doi:10.1038/s41389-022-00416-4 * These authors have contributed equally to this work. |
Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Maloujahmoum, N., Agirman, F., Bellahcene, A., & Peulen, O. (14 December 2021). Myoferlin targeting primes ferroptosis in pancreatic cancer cells [Poster presentation]. GIGA cancer day. |
Dumont, E., De Bleye, C., Rademaker, G., Coic, L., Horne, J., Sacre, P.-Y., Peulen, O., Hubert, P., & Ziemons, E. (01 March 2021). Development of a prototype device for near real-time surface-enhanced Raman scattering monitoring of biological samples. Talanta, 224, 121866. doi:10.1016/j.talanta.2020.121866 |
Gupta, S., Yano, J., Mercier, V., Htwe, H. H., Shin, H. R., Rademaker, G., Cakir, Z., Ituarte, T., Wen, K. W., Kim, G. E., Zoncu, R., Roux, A., Dawson, D. W., & Perera, R. M. (March 2021). Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth. Nature Cell Biology, 23 (3), 232 - 242. doi:10.1038/s41556-021-00644-7 |
Anania, S., Peiffer, R., Rademaker, G., Hego, A., Thiry, M., Deldicque, L., Francaux, M., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (21 June 2020). Myoferlin is a yet unknown interactor of the mitochondrial dynamics’ machinery in pancreas cancer cells. Cancers, 12 (6), 1643. doi:10.3390/cancers12061643 |
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., KOOPMANSCH, B., MacKay, G. M., Chiavarina, B., Costanza, B., Rademaker, G., Durieux, F., Agirman, F., Maloujahmoum, N., Cusumano, P. G., LOVINFOSSE, P., Leung, H. Y., LAMBERT, F., Bours, V., ... Bellahcene, A. (04 February 2020). Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Reports, 30 (5), 1400-1416.e6. doi:10.1016/j.celrep.2020.01.012 |
Anania, S., Rademaker, G., Peiffer, R., Hego, A., Deldicque, L., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (February 2020). Role of myoferlin in mitochondrial dynamics and metabolic fitness of pancreas cancer [Poster presentation]. BACR Annual Meeting 2020 - Cancer metastases: from bedside to bench, Brussels, Belgium. |
Rademaker, G. (30 January 2020). WJ460, a new drug targeting myoferlin, leads to ferroptosis and mitophagy in pancreatic cancer cells [Paper presentation]. 14th Meeting of the FRS-FNRS Contact Group on Oxidative Processes and Antioxidants. |
Anania, S., Rademaker, G., Bellahcene, A., Castronovo, V., & Peulen, O. (December 2019). Role of myoferlin in mitochondrial dynamics and metabolic fitness of Pancreatic Ductal Adenocarcinoma [Poster presentation]. Second CIRM Scientific Day, Liège, Belgium. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (December 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Poster presentation]. Cirm Annual meeting. |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (26 November 2019). Myoferlin depletion induces DNA damage response and p53- dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Metabolism in Cancer and Stromal Cells (2nd edition), Leuven, Belgium. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (November 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Poster presentation]. Bioforum Uliège. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (23 October 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Pancreatic Cancer Symposium, Toulouse, France. |
Anania, S., Rademaker, G., Wissocq, T., Bellahcene, A., Castronovo, V., & Peulen, O. (October 2019). Role of myoferlin in mitochondrial dynamics and metabolic fitness of PDAC [Poster presentation]. PANCREATIC CANCER SYMPOSIUM, Toulouse, France. |
Costanza, B., Rademaker, G., Turtoi, A., Bellahcene, A., Castronovo, V., & Peulen, O. (October 2019). TGFBI, an ECM interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration [Poster presentation]. Pancreatic Cancer Symposium 2019, Toulouse, France. |
Anania, S., Rademaker, G., Wissocq, T., Bellahcene, A., Castronovo, V., & Peulen, O. (06 September 2019). Role of myoferlin in mitochondrial dynamics and metabolic fitness of pancreas cancer [Poster presentation]. EDT Cancerology 2019, Bruxelles, Belgium. |
Peulen, O., Rademaker, G., Anania, S., Turtoi, A., Bellahcene, A., & Castronovo, V. (August 2019). Ferlin overview: from membrane to cancer biology. Cells, 8, 954. doi:10.3390/cells8090954 |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (13 June 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Belgian Society for Cell and Developmental Biology - Spring Meeting, Liège, Belgium. |
Rademaker, G. (June 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic cancer cells by enhancing the migratory capacity through the control of oxidative phosphorylation [Paper presentation]. Giga Cancer Seminar. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Di Valentin, E., Goval, J.-J., Bellahcene, A., Castronovo, V., & Peulen, O. (June 2019). Myoferlin contributes to the metastatic phenotype of pancreatic cancer cells by enhancing their migratory capacity through the control of oxidative phosphorylation. Cancers, 11 (6). doi:10.3390/cancers11060853 |
Costanza, B., Rademaker, G., Tiamiou, A., De Tullio, P., Leenders, J., Blomme, A., Bellier, J., Bianchi, E., Turtoi, A., Delvenne, P., Bellahcene, A., Peulen, O.* , & Castronovo, V.*. (2019). TGFBI, an ECM interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration. International Journal of Cancer. doi:10.1002/ijc.32247 * These authors have contributed equally to this work. |
Nokin, M.-J., Bellier, J., Durieux, F., Peulen, O., Rademaker, G., Gabriel, M., Monseur, C., CHARLOTEAUX, B., Verbeke, L., van Laere, S., RONCARATI, P., Herfs, M., Lambert, C., Scheijen, J., Schalkwijk, C., Colige, A., Caers, J., Delvenne, P., Turtoi, A., ... Bellahcene, A. (2019). Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. Breast Cancer Research, 21(1, 11. doi:10.1186/s13058-018-1095-7 |
Rademaker, G. (2019). Human colon cancer overexpress myoferlin to maintain a fit mitochondrial network and escape p53 dependent apoptosis [Paper presentation]. EDT Biologie Moléculaire. |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (2019). Human colon cancer overexpress myoferlin to maintain a fit mitochondrial network and escape p53 dependent apoptosis [Poster presentation]. Belgian Association for Cancer Research Congress, Anvers, Belgium. |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2019). Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis. doi:10.1038/s41389-019-0130-6 * These authors have contributed equally to this work. |
Rademaker, G., Hennequière, V., Brohée, L., Nokin, M.-J., LOVINFOSSE, P., Herfs, M., Thiry, M., Bellahcene, A., Castronovo, V., & Peulen, O. (01 July 2018). Myoferlin controls mitochondrial structure and metabolism in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness [Poster presentation]. EACR 25 50 Years, Amsterdam, Netherlands. |
Rademaker, G., Hennequière, V., Nokin, M.-J., LOVINFOSSE, P., Durieux, F., GOFFLOT, S., Bellier, J., Costanza, B., Herfs, M., Peiffer, R., Bettendorff, L., Deroanne, C., Thiry, M., Delvenne, P., Hustinx, R., Bellahcene, A., Castronovo, V., & Peulen, O. (April 2018). Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. Oncogene, 37 ((32)), 4398-4412. doi:10.1038/s41388-018-0287-z |
Rademaker, G. (2018). Myoferlin depletion induces DNA damage response and p53 dependent cell cycle arrest and apoptosis in colon cancer [Paper presentation]. Giga Cancer Day. |
Rademaker, G. (2018). Myoferlin controls mitochondrial structure and activity in pancreatic cancer and affects tumor aggressiveness [Paper presentation]. Giga Cancer ULiège. |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (2018). Myoferlin depletion induces DNA damage response and p53 dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Third Symposium of UBRC, Bruxelles, Belgium. |
Rademaker, G., Hennequière, V., Brohée, L., Nokin, M.-J., LOVINFOSSE, P., Durieux, F., Bellier, J., Costanza, B., Herfs, M., Bettendorff, L., Deroanne, C., Delvenne, P., HUSTINX, R., Bellahcene, A., Castronovo, V., & Peulen, O. (2018). Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma and affects tumor aggressiveness [Poster presentation]. Bioforum Uliège. |
Rademaker, G., Hennequière, V., Brohée, L., Nokin, M.-J., LOVINFOSSE, P., Durieux, F., GOFFLOT, S., Bellier, J., Costanza, B., Herfs, M., Peiffer, R., Anania, S., Bettendorff, L., Deroanne, C., Thiry, M., Delvenne, P., HUSTINX, R., Bellahcene, A., Castronovo, V., & Peulen, O. (2018). Myoferlin controls mitochondrial structure and activity in pancreatic cancer and affects tumor aggressiveness [Poster presentation]. Belgian Association for Cancer Research Congress. |
Rademaker, G., Hennequière, V., Brohée, L., Nokin, M.-J., LOVINFOSSE, P., Durieux, F., GOFFLOT, S., Bellier, J., Costanza, B., Herfs, M., Peiffer, R., Bettendorff, L., Deroanne, C., Delvenne, P., Hustinx, R., Bellahcene, A., Castronovo, V., & Peulen, O. (22 September 2017). Myoferlin controls mitochondrial structure in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness [Poster presentation]. Second U-CRC Symposium, Bruxelles, Belgium. |
Rademaker, G. (June 2017). Myoferlin a key protein in mitochondrial function, the case of pancreatic cancer [Paper presentation]. Giga-Cancer. |
Rademaker, G., Hennequière, V., Peixoto, P., Bellahcene, A., Castronovo, V., & Peulen, O. (01 February 2017). Myoferlin, a new autophagy player in pancreatic cancer cells [Poster presentation]. Giga-Day, Liège, Belgium. |
Rademaker, G. (2016). Validation of a Multiplex HPLC MS/MS assay for the measurement of steroid hormones [Master’s dissertation, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/211494 |